AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|
28.5 C
New York
Sunday, July 26, 2026

Tag: containment

2XU Named Official Compression Partner of Halifax Tides FC

World-leading compression brand joins one of Canada's rising professional football clubs to support athlete preparation, performance and recovery.HALIFAX, NS, June 10, 2026 /CNW/ --...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Haemonetics Updates Financial Reporting Segments

BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient...

2XU Brings World-Leading Compression to Reigning NSL Champions Vancouver Rise FC

Global compression brand joins the reigning National Soccer League (NSL) champions to power the next level of athlete performanceVANCOUVER, BC, June 4, 2026 /CNW/...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Persist AI Teams up with Microsize and Micromacinazione (Micmac) to Launch First-of-Its-Kind Early-Stage “Micromill” Formulation Platform, Enabling Drug Development Decision With Milligrams of API

New collaboration delivers a fully integrated formulation workflow from early solubility studies to high-throughput dissolution, stability, and in-process analytics, making drug formulation less artisanal...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Statement – Update from the Canadian Food Inspection Agency on a revised regulatory approach to the Livestock Traceability Regulations

OTTAWA, ON, June 2, 2026 /CNW/ - A strong traceability program is critical for rapid identification and containment of animal disease to maintain market...

Bargoose Home Textiles’ Patented BugStop® Seal Earns Independent Bed Bug Certification from Snell Scientifics in 2026 Hospitality Encasement Line

Women-Owned, GSA-Eligible New York Manufacturer Releases Expanded 2026 Product Guide as Hotel Operators Face $2,000–$10,000 Per-Room Losses From Single Bed Bug IncidentsLYNBROOK, N.Y., June...

Cyware Expands Threat Intelligence Suite with new Digital Risk Protection

New Integrated DRP Capabilities powered by SOCRadar Combine External Visibility with Live Threat Context to Trigger Automated Defensive Actions in Real TimeNEW YORK, June...

West Appoints Michel Lagarde to be President and Chief Executive Officer

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical...

Alberta Energy Regulator penalizes Terroco Industries Ltd. for contraventions

Calgary, Alberta, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Alberta Energy Regulator (AER) has issued an administrative penalty totaling $448 980.49 to Terroco Industries Ltd. (Terroco) for contravening the Oil and Gas Conservation Rules. A copy of the decision is on the AER’s Compliance Dashboard.   
  
Following an investigation by the AER, it was determined that over a 40-day non-contiguous period, between June 27 and August 22, 2023, Terroco contravened section 8.150(3)(c) of the Oil and Gas Conservation Rules. The investigation also determined four contraventions of section 8.030(2) of the Oil and Gas Conservation Rules.    
  
The contraventions include accepting waste not approved to receive; using a single-walled aboveground storage tank without secondary containment, leak detection, or a spill control device in use; and not having a foundation designed for an aboveground storage tank for which the AER assessed an administrative penalty of $150 000.   
  
Terroco also generated revenue performing a prohibited act, which is considered an economic benefit while contravening 8.150(3)(c) of the Oil and Gas Conservation Rules, for which the AER assessed an administrative penalty of $298 980.49.   
  
An administrative penalty is one of many compliance and enforcement tools the AER can use when companies do not comply with the regulatory requirements.    
  
For more information on the AER’s investigation enforcement processes, please see the Investigations webpage on aer.ca.  
  
About the Alberta Energy Regulator   
The AER provides for the safe, efficient, orderly, and environmentally responsible development of energy and mineral resources in Alberta through our regulatory activities. For more information visit aer.ca.   
   
Contact    
Email: media@aer.ca | Media line: 1-855-474-6356   
   
Connect with AER   
X | LinkedIn | Facebook    
  

Solventum Announces Launch of Secondary Offering of Common Stock

ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV, "Company" or "Solventum") today announced the launch of a secondary offering (the "Offering")...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsContainment